Experimental peptide analog

Adamax

The app lists Adamax as an experimental analog of Semax with a half-life of about 1 hour, and no study of Adamax itself was identified in PubMed, ClinicalTrials.gov or DailyMed.

Limited evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Adamax after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.

Drawn from the half-life in the app's model, ~1 h. The model's figures

Compound
Adamax
Symbol
ADX
Family
Cognitive and sleep peptides
Parts
8
References
4
Checked
Last reviewed . Sources are listed below.
1

Overview

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
90%
Typical dose
0.3–1 mg/day
Route
SubQ
Time to peak
~0.5 h

The app lists Adamax as an experimental modified analog of Semax, with the synonyms N-acetyl Semax adamantyl and acetyl Semax adamantyl. The app's note describes the modification as N-terminal acetylation plus an adamantyl group, added for greater metabolic stability and lipophilicity. None of the records identified in the searches below measured stability or lipophilicity for Adamax. The app's figures are a half-life of about 1 hour, 90% bioavailability by subcutaneous injection, a time to peak of about 0.5 hours and a typical range of 0.3 to 1 mg/day. The app's note states that dose, route and timing are extrapolated from Semax, not established, and that there are essentially no formal human trials. The app grades the evidence as limited. The search on Semax pharmacokinetics returned 2 records, neither reporting a half-life for Adamax, and none of the cited texts gives a figure for Adamax bioavailability, time to peak or dose range, so the app's figures stand without a published figure beside them.

2

How it works

Magrì and colleagues (Consiglio Nazionale delle Ricerche and University of Catania, Journal of Inorganic Biochemistry, 2016) describe Semax as "a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that encompasses the sequence 4-7 of N-terminal domain of the adrenocorticotropic hormone".1 The same paper studied an N-terminally acetylated Semax (Ac-Semax) in chemistry and cell-culture work, not in animals or people, and does not describe an adamantyl group.1 The authors report that "Semax acetylation did not protect from Cu(II) induced toxicity on a SH-SY5Y neuroblastoma cell line".1 They conclude this demonstrates "the crucial role played by the free NH2 terminus in the cell protection".1 The PubMed record also reports that both peptides were able to form Zn(II) complex species with comparable strength, and that peptide group acetylation does not affect the Zn(II) influx in neuroblastoma cells.1 The PubMed record lists the work as "Research Support, Non-U.S. Gov't" and does not state a commercial sponsor or the authors' limitations.1 How Ac-Semax relates to Adamax is not stated in that record, and a result in cells for one acetylated form is not a result for Adamax.1

Radchenko and colleagues (Belgorod State National Research University and the Kurchatov Institute, Acta Naturae, 2025) gave Semax or a Semax derivative to APP/PS1 mice, a mouse model of Alzheimer's disease.2 The dose was "dose of 50 μg per kg, starting from the age of 6 months", and the authors report that "both Semax and its derivative improved cognitive functions in mice".2 In the same paper the derivative did not significantly affect the number of entries into the target zone in the Barnes maze, plaque counts fell in both groups with Semax "the more efficient" of the two, and the number of animals per group was n = 10.2 That derivative is the heptapeptide Met-Glu-Asp-Arg-Pro-Gly-Pro with two amino acid substitutions, so it is not Adamax.2 The work was "supported by the Russian Science Foundation", and the paper reports intranasal use in mice, which is animal evidence on Semax and a different derivative.2 The paper's text does not state limitations, and its acknowledgments credit a State Assignment to the Kurchatov Institute for the "peptide design and synthesis".2

3

Human studies

No controlled trial or other human study of Adamax was identified in PubMed, ClinicalTrials.gov or DailyMed. The only human result shown is for Semax, a different compound, and it cannot be read as a result for Adamax.

Table 3.1Human studies1 row
Study and yearDesignPeopleDose and lengthMain result
Gusev and colleagues, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018 (Semax, not Adamax)3Clinical trial with semax+ and semax- subgroups in early and late rehabilitation groups3110 patients after ischemic stroke3Semax, 2 courses of 6000 mcg/day for 10 days with a 20 day interval3Plasma BDNF levels increased with semax and remained high through the study period; in the semax- subgroups high BDNF plasma levels were positively correlated with early rehabilitation, and semax with high BDNF levels accelerated the improvement and ameliorated the final outcome of Barthel score index; adverse events are not reported in the PubMed record3

Deeper analysis: Gusev and colleagues, Semax after ischemic stroke

Gusev and colleagues, of the Pirogov Russian National Research Medical University and the Moscow Centre for Research and Practice in Medical Rehabilitation, examined 110 patients after ischemic stroke.3 They measured plasma BDNF levels, motor performance on the British Medical Research Council scale and the Barthel index.3 The results report a positive correlation between BDNF plasma levels and Barthel score and a correlation between early rehabilitation and motor performance improvement, and the correlation between BDNF plasma levels and Barthel score was modified by the timing of rehabilitation.3 The authors conclude that "Early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance".3 The PubMed record gives no numerical effect sizes, interval or p-value, no randomisation or blinding, no adverse event or discontinuation data, no stated limitations and no funding statement, so those cannot be reported here.3 A further PubMed record, Shevchenko and colleagues (Doklady Biological Sciences, 2013), is titled "Stability of Semax acetyl to proteolysis in various biological media", but PubMed holds no summary for it, so no result can be given.4

4

What is not known

Sources in this part

  1. 3Gusev et al., 2018

No human or animal study of Adamax absorption, half-life, duration of action or safety was identified in PubMed, ClinicalTrials.gov or DailyMed. No study comparing Semax with Adamax was identified, so it is not known whether findings on Semax apply to Adamax. The word Adamax alone matches 40 PubMed records, and the 20 listed carry titles on machine-learning methods and image or signal classification, not this compound. None of the cited texts gives an Adamax figure to set beside the app's half-life, bioavailability, time to peak and dose range; the one Semax trial cited used 6000 mcg/day, which is for a different compound.3

5

Frequently asked questions

What is Adamax?

The app lists Adamax as an experimental modified analog of Semax, also named N-acetyl Semax adamantyl.

What is the half-life of Adamax?

The app lists about 1 hour, and a published figure for Adamax was not identified.

Has Adamax been tested in people?

No human study of Adamax was identified in PubMed or ClinicalTrials.gov.

Is Adamax approved?

No DailyMed label named Adamax was identified on 16 November 2026.

Is Adamax the same as Semax?

No, the app lists Adamax as a modified analog of Semax, and no study comparing the two was identified in PubMed.

Has Semax been studied in people?

A clinical trial in 110 patients after ischemic stroke reported higher plasma BDNF levels with semax, and its PubMed record does not report adverse events.3

Does acetylating Semax change how it behaves in cells?

Magrì and colleagues reported that acetylation did not protect from Cu(II) induced toxicity on a SH-SY5Y neuroblastoma cell line, in laboratory work and not in people.1

7

References

  1. Magrì A, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem 2016. PMID 27586814
  2. Radchenko AI, et al. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta Naturae 2025. PMID 41479572
  3. Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018. PMID 29798983
  4. Shevchenko KV, et al. Stability of Semax acetyl to proteolysis in various biological media. Dokl Biol Sci 2013. PMID 23652441